Iterum Therapeutics PLC Asset Resilience Ratio
Iterum Therapeutics PLC asset resilience ratio. Iterum Therapeutics PLC (ITRM) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Iterum Therapeutics PLC liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Iterum Therapeutics PLC (2016–2024)
Asset resilience ratio of Iterum Therapeutics PLC from 2016 to 2024. This chart shows how Iterum Therapeutics PLC's Asset Resilience Ratio has changed over time. Read Iterum Therapeutics PLC (ITRM) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Iterum Therapeutics PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ITRM total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Iterum Therapeutics PLC maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Iterum Therapeutics PLC Industry Peers by Asset Resilience Ratio
Compare Iterum Therapeutics PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Iterum Therapeutics PLC Asset Resilience Ratio by Year (2016–2024)
Iterum Therapeutics PLC asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Iterum Therapeutics PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $44.59 Million | -- |
| 2023-12-31 | 68.01% | $17.86 Million | $26.26 Million | +8.59pp |
| 2022-12-31 | 59.42% | $39.71 Million | $66.83 Million | +0.52pp |
| 2021-12-31 | 58.90% | $53.90 Million | $91.51 Million | +51.70pp |
| 2020-12-31 | 7.20% | $2.36 Million | $32.79 Million | +7.19pp |
| 2019-12-31 | 0.00% | $1.14K | $25.75 Million | -40.87pp |
| 2018-12-31 | 40.87% | $40.00 Million | $97.87 Million | -24.85pp |
| 2017-12-31 | 65.72% | $30.73 Million | $46.76 Million | +64.22pp |
| 2016-12-31 | 1.50% | $404.00K | $26.92 Million | -- |
About Iterum Therapeutics PLC
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with lim… Read more